Michelle Miller
Psychiatric/Mental Health · Pendleton, SCNPI 1447857925
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.3% of the total across 322 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 21.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,317 and has fallen 89.3% since, to $141 in 2025.
Across 322 payments — averaging $13.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$969
- Takeda Pharmaceuticals U.S.A., Inc.$450
- Otsuka America Pharmaceutical, Inc.$386
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$309
- Johnson & Johnson$302
- Supernus Pharmaceuticals, Inc.$266
- plus $2K from 22 others
What the payments were for
- Food & beverage$4,34697%
- Education$1223%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$4,468 in reported general payments places this provider in the 85th percentile of 354 psychiatric/mental health providers in South Carolina.
See all psychiatric/mental health providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 13 | $109,747 |
| VraylarCariprazine Hcl | 28 | $41,143 |
| FanaptIloperidone | 13 | $26,401 |
| CaplytaLumateperone Tosylate | 12 | $21,376 |
| NuedextaDextromethorphan Hbr/Quinidine | 13 | $20,128 |
| BelsomraSuvorexant | 12 | $5,033 |
| Tizanidine Hcl | 12 | $1,227 |
| Aripiprazole | 29 | $895 |
| Quetiapine Fumarate | 63 | $582 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 20 | $573 |
| Escitalopram Oxalate | 44 | $511 |
| Clonazepam | 80 | $463 |
| Doxepin Hcl | 14 | $458 |
| Bupropion XlBupropion Hcl | 25 | $448 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 25 | $417 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $152 | $109,74713 claims |
| AbbVieVraylar | $969 | $41,14328 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $220 | $26,40113 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $309 | $21,37612 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $39 | $20,12813 claims |
| MerckBelsomra | $16 | $5,03312 claims |
| Almatica Pharma LLCSertraline Hcl | $15 | $10339 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 354 psychiatric/mental health providers in South Carolina.
Other psychiatric/mental health in Pendleton
- Steven KrozerGreenville$139K
- Luron FlemingGreenville$61K
- Cerrissa HugieCharleston$54K
- Karen FulwoodMyrtle Beach$30K
- Taylor CrewsIsle Of Palms$28K
- Lauren DyerGreenville$16K
- Melissa BrownGreenville$16K
- Mary McManusNorth Myrtle Beach$15K
- Kelsie FowlerAnderson$15K
- William HendricksGreenville$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.